-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CM-101 in Liver Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CM-101 in Liver Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CM-101 in Liver Fibrosis Drug Details: CM-101 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CM-101 in Primary Sclerosing Cholangitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CM-101 in Primary Sclerosing Cholangitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CM-101 in Primary Sclerosing Cholangitis Drug Details: CM-101 is under development...
-
Product Insights
NewNet Present Value Model: Purple Biotech Ltd’s CM-24
Empower your strategies with our Net Present Value Model: Purple Biotech Ltd's CM-24 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CM-24 in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CM-24 in Pancreatic Ductal Adenocarcinoma Drug Details: CM-24 is under development for pancreatic cancer, melanoma, ovarian cancer,...
-
Product Insights
Likelihood of Approval Analysis for Familial Amyloid Cardiomyopathy
Overview How likely is it that the drugs in Familial Amyloid Cardiomyopathy will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Familial Amyloid Cardiomyopathy Overview Familial amyloid cardiomyopathy (FAC), or transthyretin amyloid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acoramidis Hydrochloride in Familial Amyloid Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acoramidis Hydrochloride in Familial Amyloid Cardiomyopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acoramidis Hydrochloride in Familial Amyloid Cardiomyopathy Drug Details: BBP-265 (AG-10)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Hyaluronidase (Recombinant, Human) + Immune Globulin (Human)) in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Hyaluronidase (Recombinant, Human) + Immune Globulin (Human)) in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Hyaluronidase (Recombinant, Human) + Immune Globulin...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Picotamide in Migraine
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Picotamide in Migraine report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Picotamide in Migraine Drug Details: Picotamide (CM-01) is under development for the prophylaxis...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NovoCardia in Left Ventricular Dysfunction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NovoCardia in Left Ventricular Dysfunction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NovoCardia in Left Ventricular Dysfunction Drug Details: Cell therapy is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALXN-2220 in Amyloid Cardiomyopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALXN-2220 in Amyloid Cardiomyopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALXN-2220 in Amyloid Cardiomyopathy Drug Details: NI-301 is under development for...